Get started

Biotechnology

FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10% price rise in the after-hours which is typically a busy trading period for biotechnology penny stocks. I will take a long trade on FULC in after hours and take off a part of the position in the next trading day and hold the rest through the weekend.
NASDAQ:FULCLong
by AwesomeAvani
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani
VRPX Biotechnology Penny Stock Post EarningsVRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced on the potential of future earnings. The short and long-moving averages ratio shows bullish momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over the POC line so it is higher than the mean of the share price traded for the duration of the volume profile. I see this as a risky long setup expectant of a 40% profit based on the target of the YTD high in February.
VLong
by AwesomeAvani
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings report of last week. An uptrend is seen after the earnings. This has been a significant reversal sustained over the past month with price rising above the support / demand zone below it. At present, price is one standard deviation below VWAP making it undervalued and ascending. I see this as a risky long trade like many biotechology penny stocks but with a decent probability of profit in consideration of a target of 6.15 which is the top of the long term high volume area. the stop loss is just below the POC line of the volume profile at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of 1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this week. If it is favorable, BLUE could go parabolic to hit the target in a day or two. If not, it will be time to exit the trade.
NASDAQ:BLUELong
by AwesomeAvani
7
IMGN Biotech Post Earnings IMGN had great earnings the last days of April and has been trending up ever since. It is riding the upper Bollinger band consistently in this past wee. The volume spike after earnings has subsided but ongoing volume is at about 5X the moving average of early April and March. Increased volume supports price momentum. The volume spike here is obvious and significant. IMGN announced a public offering. I see this as a positive. It is primed for increasing growth but needs the fuel. Interest rates are high. Stock offering will raise cash and all shareholders will be rewarded. IMGN is resting and consolidated in a narrow range during this public offering. See also the favorable article from IBD linked below. I see IMGN as a solid swing long until the next earnings. I will watch for an uncoiling upon completion of the offering with resumption of momentum moving forward.
ILong
by AwesomeAvani
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity. On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy. On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
AMEX:LABULong
by AwesomeAvani
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval; They are basically selling a generic version of an approved medication and bypassing the patent protections and betting they will fly under the regulator radar apparatus. As might be expeted this recent nano-IPO is highlly volatile. Play with it only if you have the requisite skills to do so and only with risk capital. it does the marketing through direct to consumer telehealth services. >>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< On review and analysis on the 30 minute chart, the price action is squeezing down in a flat bottom triangle likely setting up a breakout upside. The RSI oscillator shows RSI crossing 50% from below. Volatility is compressing down inside the triangle for a squeeze set up. Targets are based on the supply and demand zones of the Luxalgo indicator. The first parget is the midline between the zones while the final target is just below the supply zone. As can be seen on the chart, the first target is about 100% upside while the final target is 200% upside. One of the position is closed at each target making the return 150% overall. Stop loss is below the demand zone. A stop loss is 15% yields an overall reward to risk ration of 10:1.
NASDAQ:MGRXLong
by AwesomeAvani
APLT Biotech NASDAQ Penny LONGApplied Therapeutics is an uptrending biotechnology company that has earnings in prior quarters and is heading into another earnings report about may 11th. The run up in price cction is largely on the proposition of future growth much like TSLA back in the day. On the chart besides the obvious uptrend, the volume indicator shows a dramatic volume surge compared with the running 50 day average while the MACD shows the lines above the histogram and running upward and parallel. The ideal entry would be a pullback as the price is now quite extended however I do not believe that will occur until at least after earnings. I believe this strong runner will continue until earnings unabated. As a penny stock many shares can be taken and then the position can be closed in partials along the way thus taking profits and decreasing the risk in steps. The same applies to the call options.
NASDAQ:APLT
by AwesomeAvani
1
PFE Large Cap Pharma increased its dividendPFE just raised its dividend On the chart it has been trending downward as shown also by a down sloping anchored VWAP bands. Price is currently sitting at long term support and two standard deviations below VWAP. It appears to be ready to reverse from the deep undervalued area. In confirmation, teh voume indicator shows moderate increased relative volume compared with March. I see this as a good opportunity to enter a swing long trade or investment. PFE has its increased dividend as a hint to shareholders of increasing earnings also with the next generation of COVID vaccines in the pipeline along with a diversified line of other products. The only thing that will slow PFE down in federal legislation to limit the retail MSRP prices of its products to all consumers including those with no insurance and commercial coverage outside federal programs. PFE is solid as a rock. I see the buy signal.
NYSE:PFELong
by AwesomeAvani
2
TNYA Biotechology Penny NASDAQ LONGTNYA has been in consolidation the past two days being in the flag of a bull flag pattern on the 1H chart. Earnings about six weeks ago were solid especially for a biotechnology stock which are generally priced based on future potential and not current performance. ( Fundamentally TNYA is in the gene splicing /slicing place which is perhaps the most lucrative and therapeutic of all of the various areas in the biotechnology realm. Seemingly, its potential is expodentially high. ) The zero lag MACD lines have crossed under the histogram which in general can be considered as a buy signal. The histogram has flipped to positive. Upside to the overhead resistance zone by the Luxalgo indicator is from an entry of about 5 to 6 or about 20%. Very recent high relative volume as compared with the 50 day moving average further supports a long trade at this time. The stop loss would be $.02 below the POC line of the volume profile. I will play this with options to further leverage the price action. Both options and stock are inexpensive for a small account.
NASDAQ:TNYALong
by AwesomeAvani
MGRX Biotech Penny Stock Pullback for Continuation LONGMGRX with some FDA news catalyst got a lot of action on the last session of the week. With the pullback and overwhelming volume during the session, a continuation into the upcoming week is entirely reasonable. ( see also the link) MGRX had a last price of about $1.50 about a 50% retracement from the high of the day. I will take a position at market price in the pre-market opening the week. The target will be $2.25 or midway between the current price and the high of the last session. This will represent a 50% Return on Trading Position. I will set a stop loss at $ 1.40 representing a 10% loss. Price at present is sitting on a confluence of support of both the 20 and 50 HMAs along with the lowermost VWAP band. The reward for risk is 5X. MGRX does not have options. I expect the long trade to hit the continuation target in less than 5 days. I will set a buy-stop order to take a position when the price exceeds $ 1.55 with a stop loss of $0.15 to account for the expected volatility.
NASDAQ:MGRXLong
by AwesomeAvani
ACHV a Biotech company after earningsACHV on the 4H seems to be demonstrating a "High Bull Flag Pattern" after a big uptrend to start the year. Earnings on Thursday 3/16 were quite favorable.On the relative volume indicator Friday, May 17th showed a paradoxical huge selling volume spike to finish out this week. ( I mislabelled this as upcoming on the chart) Paradoxically, the last earnings report in November was poor but resulted in strong upward price action. The MACD histogram is at the zero line. Will ACHV resume the uptrend after earnings? Was the selling volume an institutional trader fake out to set up a lower price to buy call options? According to Tip Ranks, the analysts give ACHV a high rating with significant upside. See the link below Who knows but this may be worth watching for signs of buying volume and accumulation to fuel bullish momentum.
NASDAQ:ACHV
by AwesomeAvani
1
NVAX - Novavax Biotech Short or not?NVAX as seen on the weekly chart has been in price distress for a long time. It has only one product on the market due to various issues with the FDA process. It has a variety of products in development as linked below. The question is whether it will run out of cash before a sustained revenue stream develops. FDA approvals for the pipeline products could take years ( the days of emergency approvals for COVID and related are over) It would seem that a rich uncle like Moderna ( MRNA) would codcme around with a take-over offer that could send shares into a moonshot to back when NVAX thrived before its 95% price decline in the past two years. This seems to be a great short swing play until more products come to market or a take-over is announced. This is affirmed by the MACD histogram being persistently negative for the long-term.
NASDAQ:NVAXShort
by AwesomeAvani
1
PLSE Earnings Play Long Biotech Pulse Biosciences broke out today from a positive earnings report. Biotechnology stocks often burn cash on a slow growth cycle. This company is making money and so the expected reaction occurred. The volume indicator shows selling pressure in the lead-up to today's earnings. After the report, the reversal to buying pressure occurred nearly immediately. The MACD lines crossed under the histogram and then quickly reached the horizontal zero line serving as a confirmation. I expect a good follow-through next week. This may be a great penny stock to trade or even invest.
NASDAQ:PLSELong
by AwesomeAvani
Bayer AG (BAYN.de) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the German company Bayer AG (BAYN.de). Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 60.750 EUR. According to experts, your stop-loss order should be placed at 54.890 EUR if you decide to enter this position. Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, in an interview with Reuters, said the company increased U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years and plans to expand on that by another 75% by 2030. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by DivergenceSeeker
3
JAGX | Close to a Bottom? | BounceJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
NASDAQ:JAGXLong
by DivergenceSeeker
5